• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生活质量问卷的反应度和最小重要得分差异:多发性骨髓瘤患者中 EORTC QLQ-C30 癌症特异性问卷与通用效用量表 EQ-5D 和 15D 的比较。

Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.

机构信息

Department of Haematology, Oslo University Hospital, Ullevaal Faculty of Medicine, University of Oslo, Oslo, Norway.

出版信息

Eur J Haematol. 2011 Oct;87(4):330-7. doi: 10.1111/j.1600-0609.2011.01665.x. Epub 2011 Jul 26.

DOI:10.1111/j.1600-0609.2011.01665.x
PMID:21668504
Abstract

OBJECTIVES

The aims of this study were to (i) compare the responsiveness of the EORTC QLQ-C30 cancer-specific questionnaire and the generic questionnaires EQ-5D and 15D used for economic evaluation of healthcare interventions and (ii) determine the minimal important differences (MIDs) in these questionnaires. The MID is the smallest change in a quality-of-life score considered important to patients.

METHODS

Between 2006 and 2008, 239 patients with multiple myeloma completed the questionnaires at inclusion (T1) and after 3 months (T2). At T2, patients were asked whether they had noticed any change in their quality of life. Responsiveness and MIDs were determined by mean score changes (T2-T1) for patients who, in the interview, stated they had improved, deteriorated, or were unchanged. Responsiveness was also assessed using standardized response means. Wilcoxon tests for pair differences were used to evaluate the statistical significance of the changes.

RESULTS

Patients who improved had significantly (P < 0.01) higher scores at T2 in all three questionnaires. Patients who deteriorated reported lower scores at T2; however, for the 15D, the differences in score were not statistically significant. The MIDs for the QLQ-C30, EQ-5D, and 15D were 8, 0.08, and 0.03 in patients who improved and 12, 0.10 and 0.02 in patients who deteriorated, respectively.

CONCLUSIONS

All three questionnaires showed an acceptable responsiveness in patients who improved. However, the 15D did not respond optimally in patients who deteriorate and cannot be recommended for use in patients with myeloma.

摘要

目的

本研究旨在:(i) 比较 EORTC QLQ-C30 癌症特异性问卷与用于医疗保健干预经济评估的通用问卷 EQ-5D 和 15D 的反应能力,以及 (ii) 确定这些问卷的最小重要差异 (MID)。MID 是患者认为重要的生活质量评分的最小变化。

方法

在 2006 年至 2008 年期间,239 名多发性骨髓瘤患者在纳入时 (T1) 和 3 个月后 (T2) 完成了问卷。在 T2 时,患者被问及他们是否注意到生活质量有任何变化。通过在访谈中表示有所改善、恶化或保持不变的患者的平均评分变化 (T2-T1) 来确定反应能力和 MID。还使用标准化反应均值来评估反应能力。使用 Wilcoxon 检验对差值进行配对差异的统计显著性评估。

结果

在所有三个问卷中,报告改善的患者在 T2 的得分明显更高 (P < 0.01)。报告恶化的患者在 T2 的得分较低;然而,对于 15D,评分的差异无统计学意义。在有所改善的患者中,QLQ-C30、EQ-5D 和 15D 的 MID 分别为 8、0.08 和 0.03,在恶化的患者中,分别为 12、0.10 和 0.02。

结论

在有所改善的患者中,所有三个问卷都表现出可接受的反应能力。然而,15D 在恶化的患者中反应不佳,不建议用于骨髓瘤患者。

相似文献

1
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.生活质量问卷的反应度和最小重要得分差异:多发性骨髓瘤患者中 EORTC QLQ-C30 癌症特异性问卷与通用效用量表 EQ-5D 和 15D 的比较。
Eur J Haematol. 2011 Oct;87(4):330-7. doi: 10.1111/j.1600-0609.2011.01665.x. Epub 2011 Jul 26.
2
What changes in health-related quality of life matter to multiple myeloma patients? A prospective study.多发性骨髓瘤患者关注哪些与健康相关的生活质量变化?一项前瞻性研究。
Eur J Haematol. 2010 Apr;84(4):345-53. doi: 10.1111/j.1600-0609.2009.01404.x. Epub 2009 Dec 22.
3
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.多发性骨髓瘤患者中欧洲癌症研究与治疗组织核心生活质量问卷C30版和骨髓瘤模块问卷MY20版与欧洲五维健康量表的映射关系
Health Qual Life Outcomes. 2014 Mar 11;12:35. doi: 10.1186/1477-7525-12-35.
4
Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.估算癌症患者 EQ-5D-5L 和 EORTC QLQ-C30 的最小重要差异。
Health Qual Life Outcomes. 2024 Sep 20;22(1):81. doi: 10.1186/s12955-024-02294-3.
5
Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.将癌症特异性 EORTC QLQ-C30 映射到偏好加权 EQ-5D、SF-6D 和 15D 工具。
Value Health. 2009 Nov-Dec;12(8):1151-7. doi: 10.1111/j.1524-4733.2009.00569.x. Epub 2009 Jun 25.
6
Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma.健康相关生活质量的最小重要差异和反应转移;多发性骨髓瘤患者的纵向研究。
Health Qual Life Outcomes. 2010 Aug 3;8:79. doi: 10.1186/1477-7525-8-79.
7
Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.多发性骨髓瘤癌症的通用型、疾病特异性和映射健康状态效用值比较。
Value Health. 2012 Dec;15(8):1059-68. doi: 10.1016/j.jval.2012.08.2201.
8
Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.荷兰乳腺癌患者术后第一年EQ-5D-5L和EORTC QLQ-C30的内部反应性:一项纵向队列研究。
Cancers (Basel). 2024 May 21;16(11):1952. doi: 10.3390/cancers16111952.
9
Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.评估将 EORTC QLQ-C30 算法映射到转移性结直肠癌成本效益模型中的 EQ-5D 指数的性能。
Health Qual Life Outcomes. 2020 Jul 20;18(1):240. doi: 10.1186/s12955-020-01481-2.
10
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.解释欧洲癌症研究与治疗组织(EORTC)生活质量问卷核心 30 评分在卵巢癌患者中的最小重要差异。
Gynecol Oncol. 2020 Nov;159(2):515-521. doi: 10.1016/j.ygyno.2020.09.007. Epub 2020 Sep 21.

引用本文的文献

1
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.达雷妥尤单抗、硼替佐米、美法仑和泼尼松联合用药与单独使用硼替佐米、美法仑和泼尼松治疗新诊断的不适于移植的多发性骨髓瘤患者的健康相关生活质量:3期OCTANS研究分析
Ann Hematol. 2025 May 23. doi: 10.1007/s00277-025-06303-3.
2
A systematic review of minimum important changes for generic multi-attribute utility instruments and recommendations for their estimation.通用多属性效用工具最小重要变化的系统评价及其估计建议。
Eur J Health Econ. 2025 Apr 16. doi: 10.1007/s10198-025-01778-3.
3
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
使用达雷妥尤单抗、来那度胺和地塞米松治疗的移植不适用新诊断多发性骨髓瘤患者的健康相关生活质量持续改善:MAIA患者报告结局的最终分析
Eur J Haematol. 2025 May;114(5):883-889. doi: 10.1111/ejh.14392. Epub 2025 Feb 14.
4
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).基于多模式可测量残留疾病阴性(MRD2STOP)指导的多发性骨髓瘤维持治疗的停药。
Blood Cancer J. 2024 Oct 7;14(1):170. doi: 10.1038/s41408-024-01156-x.
5
Geriatric assessment with management for older patients with cancer receiving radiotherapy: a cluster-randomised controlled pilot study.老年癌症患者放疗管理的老年综合评估:一项集群随机对照试点研究。
BMC Med. 2024 Jun 10;22(1):232. doi: 10.1186/s12916-024-03446-4.
6
Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16).家庭报告结局测量量表(FROM-16)的反应度和最小临床重要变化。
J Patient Rep Outcomes. 2024 Mar 26;8(1):38. doi: 10.1186/s41687-024-00703-1.
7
Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials.多发性骨髓瘤临床试验中患者报告结局的使用与报告指南。
Cancers (Basel). 2023 Dec 8;15(24):5764. doi: 10.3390/cancers15245764.
8
The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.当前治疗选择对复发/难治性多发性骨髓瘤患者健康相关生活质量的影响:临床研究的系统评价。
J Cancer Surviv. 2024 Jun;18(3):673-697. doi: 10.1007/s11764-023-01332-1. Epub 2023 Jan 16.
9
Establishing the minimal clinically important difference of the EQ-5D-3L in older adults with a history of falls.确定有跌倒史的老年人中 EQ-5D-3L 的最小临床重要差异。
Qual Life Res. 2022 Nov;31(11):3293-3303. doi: 10.1007/s11136-022-03231-x. Epub 2022 Aug 23.
10
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.基于替莫唑胺的同步放化疗或观察低级别胶质瘤后的生活质量。
J Neurooncol. 2022 Feb;156(3):499-507. doi: 10.1007/s11060-021-03920-6. Epub 2022 Jan 22.